EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models

Brian Herbst, Alex Blair, Yiming Li, Elizabeth M Jaffee, Lei Zheng

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci196622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Brian Herbst und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Pancreatic Neoplasms, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single-agent anti-PD-1 antibodies are ineffective for pancreatic ductal adenocarcinoma (PDAC) due to the immunosuppressive tumor-microenvironment (TME). KRAS mutations contribute to the inflammatory TME and therapeutic resistance by upregulating IL-8 via MAPK pathways. Thus, this study attempted to overcome the resistance to anti-PD-1 antibodies by targeting downstream KRAS-effectors. The study found that the resistance to anti-PD-1 antibodies can be overcome through MEK1/2-inhibition. The combination of anti-PD-1 antibodies and MEK inhibitors displayed antitumor activity in Kras mutated (Kras mut ) KPC mouse tumors, but not WT (Kras WT ) Panc02 tumors. The combination of anti-PD-1 antibodies and MEK inhibitors induced recruitment of tumor-associated neutrophils (TANs) via CXCR2, an IL-8 receptor, and increased memory CD8 + T cells and IFN-γ production in treatment-sensitive tumors. However, larger tumors still resisted the combination of anti-PD-1 antibody and MEK inhibitor, likely due to hypoxia/necrosis-induced NETosis and associated paucity of CD8 + T cells. The subsequent addition of anti-CXCR2 antibody overcame this resistance by blocking TAN-infiltration to hypoxic/necrotic areas. Consistently, a risk-score based on the NETosis-MAPK signaling interaction is significantly associated with poorer survival in human PDAC. This study thus provides a new venue for overcoming resistance to strategies targeting KRAS signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Interleukin-8BPancreatic NeoplasmsDrug Resistance, NeoplasmCarcinoma, Pancreatic DuctalProtein Kinase InhibitorsExtracellular TrapsNeoplasm ProteinsAnimalsMiceHumansTumor MicroenvironmentProto-Oncogene Proteins p21(ras)Cell Line, Tumor

Stichwörter der Autor:innen

CancerCancer immunotherapyDrug therapyImmunologyOncology

Substanzen

Receptors, Interleukin-8BCxcr2 protein, mouseProtein Kinase InhibitorsNeoplasm ProteinsProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center.
  • Graduate Program in Cellular and Molecular Medicine.
  • Pancreatic Cancer Precision Medicine Center of Excellence Program.
  • Bloomberg-Kimmel Institute for Cancer Immunotherapy.
  • Skip Viragh Center for Pancreatic Cancer, and.
  • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Förderung

  • National Cancer Institute

Zitieren

APA

Herbst, B., Blair, A., Li, Y., Jaffee, E. M., & Zheng, L. (2026). CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci196622

Vancouver

Herbst B, Blair A, Li Y, Jaffee EM, Zheng L. CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. Journal of Clinical Investigation. 2026. doi:10.1172/jci196622

BibTeX
@article{Herbst2026,
  author = {Herbst, Brian and Blair, Alex and Li, Yiming and Jaffee, Elizabeth M and Zheng, Lei},
  title = {CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci196622}
}
Kostenlos starten →